Hyperbaric oxygen (HBO) therapy for cardiac hypertrophy and fibrosis: Hyperbaric oxygen (HBO) therapy decreases MiR-29 expression, activates wnt- signaling and its components GSK3B, ICAT/CTNNBIP1, HBP1 and GLIS2, attenuates pathologic hypertrophy, inhibits fibrosis of the heart tissue, and improves cardiac function via up regulation of its target gene, 30/November/2020, 10. 40 pm

Krebs cycle–derived immunometabolite itaconate based therapy for COVID-19/SARS-COV-2 and other infectious diseases: 4-Octyl Itaconate, a cell-permeable derivative derived from the TCA cycle metabolite Aconitate, inhibits SARS-COV-2, Hepatitis-B/C, Dengue, Zika, Ebola, HIV-1, Mtb, Malaria, CMV, Influenza H1NI1, Foot and Mouth disease, ADV, respiratory syncytial, Sindbis, and SFV viruses and others by increasing the levels of NRF2, IFN (Interferon)-alpha/alpha-2/beta/gamma/lamda, interferon-inducible transmembrane protein IFITM3, Interferon-stimulated gene-15, Mx2 and antimicrobial peptides and decreasing the expression of inflammatory cytokines, 19/November/2020, 11.43 am
November 19, 2020
LNCRNA-based regenerative cardiovascular therapy: LncRNA SNGH1 (small nucleolar RNA host gene) inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte proliferation, regeneration, and survival after myocardial infarction, via up-regulation of its target gene, 1/December/2020, 12.55 pm
December 1, 2020
Show all

Introduction: What they say:  

A recent study from the Institute of Pharmacology and Toxicology, Technical University Munich (TUM), 80802, Munich, Germany; DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, 80802, Munich, Germany; and Mount Sinai, Cardiovascular Research Center, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA shows that “Cardiac myocyte miR-29 promotes pathological remodeling of the heart by activating Wnt signaling.” This study was published, in the 20 November 2018 issue of the journal “Nature communications (One of the best journals in general science with an impact factor of 12+), by Prof Engelhardt, Sassi and others.


What we say:

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Hyperbaric oxygen (HBO) therapy for cardiac hypertrophy and fibrosis: Hyperbaric oxygen (HBO) therapy decreases MiR-29 expression, activates wnt- signaling and its components GSK3B, ICAT/CTNNBIP1, HBP1 and GLIS2, attenuates pathologic hypertrophy, inhibits fibrosis of the heart tissue, and improves cardiac function via up regulation of its target gene, 30/November/2020, 10. 40 pm


From significance of the study to Public Health relevance:

Given that: (1) cardiovascular disease is the leading cause of death worldwide; (2) the raise of death rate, due to cardiovascular disease, has increased from 123 lakhs in 1990 to 173 lakhs in 2013; (3) 85% of people over 80 years are susceptible to cardiovascular diseases;(4) in India, in 2004, 14.6 lakhs deaths (14% of total deaths) were due to ischemic heart disease; (3) the death due to cardiovascular disease is higher in low-to-middle income countries compared to developed countries; (4) the global economic cost spent in the treatment of cardiovascular disease in 2011 was little more than 10 billion US dollars; (5) an alarming number of people, such as 230 lakhs people, will die from cardiovascular diseases from 2030 onwards; (6) over 240 lakhs people suffer from heart failure globally, with only treatment option being the heart transplant, there is an urgent need to find: (i) a way to induce regeneration of cardiomyocytes that were lost in Myocardial patients; (ii) a cheaper alternative to the existing expensive drugs; and (iv) a side-effect-free Natural product-based drug.


What is known?

Cardiac stress, in long-term, has been shown to promote pathologic hypertrophy; and fibrosis of the myocardium. Recently, Prof. Engelhardt’s research team has shown that MiRNA-29: (1) augments pathologic hypertrophy; (2) promotes cardiac dysfunction; and (3) deletion or antisense: (a) prevents cardiac hypertrophy; (b) prevents fibrosis; (c) activates the Wnt pathway components, such as GSK3B, ICAT/CTNNBIP1, HBP1 and GLIS2, suggesting that agents that decrease the expression of MiR-29 in adult cardiomyocytes may inhibit wnt pathway and improve cardiac function by attenuating cardiac hypertrophy and pathologic fibrosis.


From Research Findings to Therapeutic Opportunity:

This study suggests that Hyperbaric oxygen (HBO) therapy may aid in the treatment of cardiac hypertrophy and fibrosis. Hyperbaric oxygen (HBO), by increasing the expression of its target genes, it may decrease the expression of miR-29 (fig.1). Thereby, it may: (1) increase the expression of GSK3B, ICAT/CTNNBIP1, HBP1 and GLIS2; (2) inhibit wnt pathway; (3) increase the expression of a number of other gene products that attenuate cardiac hypertrophy and pathological fibrosis; and (4) prevent cardiac hypertrophy (fig 1). Thus, by treating patients with hyperbaric oxygen (HBO), one may prevent pathological cardiac hypertrophy and fibrosis of the myocardium. Together, this study suggests, for the first time, that Hyperbaric oxygen (HBO) therapy, either alone or in combination with other cardioprotective drugs,” may be used to improve cardiac functions (fig. 2).

Figure 1. Hyperbaric oxygen (HBO) therapy functions as a Cardioprotective agent. Mechanistic insights into how Hyperbaric oxygen (HBO) therapy decreases the expression of MiR-29 and other genes that attenuate cardiac hypertrophy and fibrosis.

Figure 2. Hyperbaric oxygen (HBO) therapy functions as a cardioprotective agent against cardiac hypertrophy and fibrosis. HBO therapy attenuates cardiac hypertrophy and fibrosis through down regulation of MiR-29

Figure 3. While it had been shown that in vivo silencing or genetic deletion of miR-29 attenuates cardiac fibrosis and cardiac hypertrophy, the study presented here suggests, for the first time, that, Hyperbaric oxygen (HBO) therapy decreases the expression of MiR-29 and attenuates cardiac dysfunction. And, thereby, it makes those who undergo Hyperbaric oxygen (HBO) therapy less susceptible to cardiac dysfunction.

Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by:

Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How does Hyperbaric oxygen (HBO) therapy decrease the expression of MiR-29 and attenuate cardiac hypertrophy and fibrosis?

Amount: $750 #

# Research cooperation

For purchase and payment details, you may reach us at admin@genomediscovery.org


References:

Web:http://genomediscovery.org or http://newbioideas.com/

Citation: Boominathan, L., Hyperbaric oxygen (HBO) therapy for cardiac hypertrophy and fibrosis: Hyperbaric oxygen (HBO) therapy decreases MiR-29 expression, activates wnt- signaling and its components GSK3B, ICAT/CTNNBIP1, HBP1 and GLIS2, attenuates pathologic hypertrophy, inhibits fibrosis of the heart tissue, and improves cardiac function via up regulation of its target gene, 30/November/2020, 10. 40 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at admin@genomediscovery.org

Comments are closed.